Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%
April 20 2020 - 6:00AM
Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian
biopharmaceutical company focused on developing and commercializing
oral immunotherapeutics for the treatment of gut mediated diseases,
today announced the sales results of its commercially available and
over-the-counter gastrointestinal and digestive health immune
supplement Travelan® for the third quarter of the fiscal year 2020
ending on March 31, 2020.
North American Travelan® sales were up by 95%
and worldwide product sales grew by 60% YoY in the third quarter of
FY20, reaching AU $983K* compared to AU $616K in Q3 FY19. YTD March
31 worldwide sales reached AU $2.67M* marking a healthy 57%
increase on the same time last year.
In Australia, Travelan® sales increased to AU
$475K* in Q3 FY20, representing a 35% increase over Q3 FY19 (AU
$350K). Co-operative marketing initiatives with Pharmacies,
including a Chemist Warehouse TV advertisement in December 2019
contributed to this growth. YTD March 31 sales in Australia reached
AU $1.43M*, 35% higher than the same time last year.
In the US, Travelan® sales continued their
upward trajectory growing by 50% YoY to AU $412K* for Q3 2020. YTD
March 31 US Sales (AU $926K*) were 46% higher than the same time
last year. This growth was attributable to increasing sales in both
Passport Health Travel Clinics and on the Amazon e-commerce
channel. A consumer awareness campaign was launched in the USA in
mid-February 2020 which generated valuable publicity for Travelan®
through a combination of earned media in digital news publications
and through Travel Influencer channels. The campaign was cut short
due to the impact that the COVID-19 pandemic had on international
travel in late March.
In Canada, Travelan® sales reached $96K* in Q3
FY20 with Loblaws commencing distribution and Shoppers Drug Mart
increasing scan sales through co-operative marketing initiatives at
store level. YTD March 31 Canadian sales were $313K* as brand
awareness starts to build in this market.
In mid to late March 2020, the COVID-19 pandemic
resulted in international travel restrictions being enacted in all
markets in which Travelan® is sold. It is anticipated these events
will impact on Travelan® sales in Q4 of FY20. The Company will look
to increase overall revenues to help mitigate the anticipated
decrease in Travelan sales – due to decreased travel – by promoting
Travelan® and Travelan®'s sister product, Protectyn®, for their gut
health benefits. The market effort will focus on the benefits that
Travelan® offers when it comes to maintaining digestive health. It
is noteworthy that when people stay at home to self-isolate, they
sometimes make poor dietary choices such as eating takeaway food
that has been transported in uncontrolled temperatures or that has
been poorly prepared, or which contains unhealthy ingredients. In
addition, stress, changing routines and weakened immunity can also
lead to digestion issues. Travelan® helps to maintain the delicate
balance of the gut microbiota by eliminating invading pathogens,
whether you are travelling or self-isolating at home.
Immuron CEO, Jerry Kanellos said “This good news
story has been overshadowed by the novel coronavirus that emerged
in the central Chinese city of Wuhan late last year. New cases are
being reported daily around the globe and the world has been
plunged into turmoil. Since then, a pandemic has been announced by
the World Health Organization and most governments have enacted
states of emergency and lockdown their borders to contain the virus
and protect their citizens. As COVID-19 has spread, we have been
monitoring its global impact on clinical trials. Major
pharmaceutical and biotechnology companies such as Pfizer, Merck,
GSK, Eli Lilly, Bristol Myers Squibb and others are delaying, or
pause trials due to the pandemic. While this is a difficult time
for so many, we have also decided to conserve our cash reserves and
suspend all work associated with the IND filing and postpone the
planned phase III clinical program for IMM-124E to prevent
Travelers’ Diarrhea which was on track to submit an IND application
to the FDA in June 2020 and to begin recruitment in July 2020 to
coincide with the Northern hemisphere summer holiday travel period.
This decision will also impact the planned clinical development of
our IMM-529 asset. The company will continue the clinical
development of a new oral therapeutic targeting travelers’ diarrhea
caused by campylobacter and enterotoxigenic E.coli pathogens with
the Naval Medical Research Centre. The protective efficacy of the
product will be evaluated in two controlled human infection model
clinical trials scheduled to commence in Q3 and Q4 next financial
year. The company will also continue to support the Uniformed
Services University’s Infectious Diseases Clinical Research Program
(IDCRP), the UK Ministry of Defense and the New York City Travel
Clinic who are jointly conducting a randomized clinical trial to
evaluate the efficacy of Travelan and two other nutraceutical
products for Travelers’ Diarrhea prevention. The randomized,
double-blind, placebo controlled multicenter clinical trial will
evaluate the effectiveness of 3 commercially available products: A
prebiotic, a probiotic and Travelan®, each vs. placebo, during
deployment of military personnel to high-TD risk regions. The first
purchase order from the Uniformed Services University for Travelan®
was delivered this year. The continuing spread of COVID-19 has
everyone's undivided attention as we grapple with its effect on our
daily lives. The pandemic has also caused significant disruptions
to global clinical development, and we send our best wishes and
heart felt support to all those whose lives and work have been
affected by this outbreak.”
*Unaudited gross revenue
COMPANY
CONTACT: Jerry Kanellos, Ph.D.Chief
Executive OfficerPh: +61 (0)3 9824 5254info@immuron.com |
About ImmuronImmuron Limited
(ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical
company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory
mediated and infectious diseases. Immuron has a novel and safe
technology platform with one commercial asset generating revenue.
In Australia, Travelan® is a listed medicine on the Australian
Register of Therapeutic Goods (AUST L 106709) and is indicated to
reduce the risk of Travellers’ Diarrhea, reduce the risk of minor
gastro-intestinal disorders and is antimicrobial. In Canada,
Travelan® is a licenced natural health product (NPN 80046016) and
is indicated to reduce the risk of Travellers’ Diarrhea. In the
U.S., Travelan® is sold as a dietary supplement for digestive tract
protection in accordance with section 403 (r)(6) of the Federal
Drug Administration (FDA).
For more information visit:
http://www.immuron.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024